for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ESSA Pharma Inc

EPIX.OQ

Latest Trade

2.86USD

Change

0.00(0.00%)

Volume

2

Today's Range

2.87

 - 

2.87

52 Week Range

1.41

 - 

4.45

As of on the TSX Venture Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.86
Open
2.87
Volume
2
3M AVG Volume
0.08
Today's High
2.87
Today's Low
2.87
52 Week High
4.45
52 Week Low
1.41
Shares Out (MIL)
20.76
Market Cap (MIL)
82.84
Forward P/E
-2.63
Dividend (Yield %)
--

Next Event

Q4 2019 ESSA Pharma Inc Earnings Release

Latest Developments

More

Essa Pharma Qtrly Loss Per Share $0.52

ESSA Says That Scheme Of Arrangement With Realm Therapeutics Has Become Effective

Realm Therapeutics Provides Update On Company’S Nasdaq Listing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ESSA Pharma Inc

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. Its pipeline also includes antinen for triple negative androgen receptor (AR+) breast cancer. Its proprietary aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting ARdriven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

Industry

Biotechnology & Drugs

Contact Info

999 Broadway W Suite 720

+1.778.3310962

http://essapharmaceuticals.com/

Executive Leadership

Richard M. Glickman

Chairman of the Board

David Ross Parkinson

President, Chief Executive Officer, Director

David Sidney Wood

Chief Financial Officer

Peter Virsik

Chief Operating Officer, Executive Vice President

Raymond L. Andersen

Chief Technology Officer, Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2017

0.0K

2019(E)

0.0K
EPS (CAD)

2016

-14.600

2017

-10.780

2018

-3.272

2019(E)

-1.520
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
38.73
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
709.93
LT Debt To Equity (MRQ)
227.02
Return on Investment (TTM)
-137.02
Return on Equity (TTM)
-91.61

Latest News

BRIEF-Essa Pharma Qtrly Loss Per Share Of $0.83

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER ENDED MARCH 31, 2018

BRIEF-ESSA Pharma Inc. Regains Compliance With Nasdaq Listing Requirements

* ESSA PHARMA INC. REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS Source text for Eikon: Further company coverage:

BRIEF-Essa Pharma Files For Resale Of 113.9 Mln Common Shares By Selling Shareholders

* ESSA PHARMA INC FILES FOR RESALE OF CO'S 113.9 MILLION COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source: (http://bit.ly/2Ft0Xh1) Further company coverage:

BRIEF-Essa Pharma Qtrly Loss Per Share $0.07

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

BRIEF-Essa Pharma Files For Offering Of About 113.9 Million Common Shares That May Be Offered For Resale By Selling Shareholders

* ESSA PHARMA INC FILES FOR OFFERING OF ABOUT 113.9 MILLION COMMON SHARES THAT MAY BE OFFERED FOR RESALE BY SELLING SHAREHOLDERS - SEC FILING Source text: (http://bit.ly/2Dsiula) Further company coverage:

BRIEF-Bvf Partners Reports 9.9 Percent Passive Stake In Essa Pharma

* BVF PARTNERS L.P REPORTS 9.9 PERCENT PASSIVE STAKE IN ESSA PHARMA INC AS OF JANUARY 5, 2018 - SEC FILING Source text - http://bit.ly/2DgNTLE Further company coverage:

BRIEF-Essa Says Intends To Issue Up To 125 Mln Common Shares At $0.20 Per Share

* ESSA ANNOUNCES FILING OF AMENDED AND RESTATED PROSPECTUS SUPPLEMENT AND AN UPDATE TO PREVIOUSLY ANNOUNCED EQUITY OFFERING

BRIEF-Essa Pharma Announces Pricing Of Previously Announced Equity Offering

* ESSA PHARMA ANNOUNCES PRICING OF PREVIOUSLY ANNOUNCED EQUITY OFFERING

BRIEF-ESSA Pharma announces overnight marketed equity offering

* ESSA PHARMA - TO USE NET PROCEEDS OF OFFERING PRIMARILY TO CONTINUE ONGOING PRECLINICAL DEVELOPMENT OF CO'S ANITEN COMPOUNDS Source text for Eikon: Further company coverage:

BRIEF-Essa Pharma Reports Qtrly Loss Per Share Of $0.07

* ESSA PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up